Treatment persistence after switching between anti-tumor necrosis factor agents and tofacitinib in ulcerative colitis: A nationwide claims-based cohort study in South Korea.
文献摘要
Background The optimal sequencing of advanced therapy in ulcerative colitis (UC) remains unclear. Data comparing different sequencing including the use of tofacitinib as first-line therapy remain scarce. Objectives We compared the treatment persistence of two therapeutic strategies: anti-tumor necrosis factor (anti-TNF) agents to tofacitinib (A→T) versus tofacitinib to anti-TNF agents (T→A). Design We conducted a retrospective, nationwide, claims-based cohort study using data from the Korean Health Insurance Review and Assessment database. Methods We included adult UC patients initiating anti-TNF agents or tofacitinib as first-line therapy. The primary outcome was second-line treatment persistence, using Kaplan-Meier method and multivariable Cox models to estimate adjusted hazard ratios (aHRs). Propensity score matching balanced baseline characteristics. Results A total of 314 patients were included (A→T, n=273; T→A, n=41). The T→A group was younger (33.0 vs 42.0 years; P=0.02), had lower concomitant use of corticosteroids at first-line therapy (36.59% vs 65.57%; P Conclusion In Korean UC patients, switching from anti-TNF agents to tofacitinib was associated with longer second-line treatment persistence than the reverse sequence.